Overview

  • Product name
    LRP6 (phospho S1490) peptide

Description

  • Nature
    Synthetic
  • Amino Acid Sequence

    Associated products

    Specifications

    Our Abpromise guarantee covers the use of ab192756 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    • Applications

      Blocking - Blocking peptide for Anti-LRP6 (phospho S1490) antibody [EP2360Y] (ab76417)

    • Form
      Liquid
    • Additional notes

      This is the blocking peptide for ab76417

      - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
      - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
      - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
      - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
      - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

    • Concentration information loading...

    Preparation and Storage

    • Stability and Storage

      Shipped at 4°C. Store at -20°C.

    General Info

    • Alternative names
      • ADCAD2
      • C030016K15Rik
      • Cd
      • FLJ90062
      • FLJ90421
      • LDL receptor related protein 6
      • Low density lipoprotein receptor related protein 6
      • Low-density lipoprotein receptor-related protein 6
      • LRP-6
      • LRP6
      • LRP6_HUMAN
      • OTTHUMP00000238979
      • OTTHUMP00000238980
      • OTTHUMP00000238982
      • STHAG7
      see all
    • Function
      Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Required for posterior patterning of the epiblast during gastrulation.
    • Tissue specificity
      Widely co-expressed with LRP5 during embryogenesis and in adult tissues.
    • Involvement in disease
      Defects in LRP6 are the cause of autosomal dominant coronary artery disease type 2 (ADCAD2) [MIM:610947].
    • Sequence similarities
      Belongs to the LDLR family.
      Contains 4 EGF-like domains.
      Contains 3 LDL-receptor class A domains.
      Contains 20 LDL-receptor class B repeats.
    • Domain
      The YWTD-EGF-like domains 1 and 2 are required for the interaction with Wnt-frizzled complex. The YWTD-EGF-like domains 3 and 4 are required for the interaction with DKK1.
      The PPPSP motifs play a central role in signal transduction by being phosphorylated, leading to activate the Wnt signaling pathway.
    • Post-translational
      modifications
      Dual phosphorylation of cytoplasmic PPPSP motifs sequentially by GSK3 and CK1 is required for AXIN1-binding, and subsequent stabilization and activation of beta-catenin via preventing GSK3-mediated phosphorylation of beta-catenin. Phosphorylated, in vitro, by GRK5/6 within and outside the PPPSP motifs. Phosphorylation at Ser-1490 by CDK14 during G2/M phase leads to regulation of the Wnt signaling pathway during the cell cycle. Phosphorylation by GSK3B is induced by RPSO1 binding and inhibited by DKK1. Phosphorylated, in vitro, by casein kinase I on Thr-1479.
      Undergoes gamma-secretase-dependent regulated intramembrane proteolysis (RIP). The extracellular domain is first released by shedding, and then, through the action of gamma-secretase, the intracellular domain (ICD) is released into the cytoplasm where it is free to bind to GSK3B and to activate canonical Wnt signaling.
      Palmitoylation on the two sites near the transmembrane domain leads to release of LRP6 from the endoplasmic reticulum.
      Mono-ubiquitinated which retains LRP6 in the endoplasmic reticulum.
      N-glycosylation is required for cell surface location.
    • Cellular localization
      Membrane. Endoplasmic reticulum. On Wnt signaling, undergoes a cycle of caveolin- or clathrin-mediated endocytosis and plasma membrane location. Released from the endoplasmic reticulum on palmitoylation. Mono-ubiquitination retains it in the endoplasmic reticulum in the absence of palmitoylation. On Wnt signaling, phosphorylated, aggregates and colocalizes with AXIN1 and GSK3B at the plasma membrane in LRP6-signalsomes. Chaperoned to the plasma membrane by MESD.
    • Information by UniProt

    References

    This product has been referenced in:
    • Suprynowicz FA  et al. Conditional cell reprogramming involves non-canonical ß-catenin activation and mTOR-mediated inactivation of Akt. PLoS One 12:e0180897 (2017). WB ; Human . Read more (PubMed: 28700668) »

    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab192756.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up